Best Hospitals for Anemia in UAE

In India, the total cost of anaemia treatment ranges from approximately $300 to $8,000 USD depending on the specific intervention required. A single intravenous iron infusion session (ferric carboxymaltose or iron sucrose) typically costs $150–$400 USD per session, with a 3-session protocol running $400–$900 USD inclusive of haematologist consultation and day-care monitoring. A comprehensive haematology workup including bone marrow biopsy with flow cytometry, cytogenetics, and FISH panel costs $800–$2,500 USD in India. At the complex end, immunosuppressive therapy for aplastic anaemia (ATG + cyclosporine + eltrombopag protocol, inpatient) may cost $4,000–$8,000 USD for the initial hospitalisation course. In the UAE (Dubai/Abu Dhabi), comparable treatments cost 50–60% more: a single IV iron infusion session ranges from $400–$900 USD; a full haematology workup with bone marrow biopsy costs $2,000–$5,500 USD; and aplastic anaemia immunosuppressive therapy inpatient costs $10,000–$18,000 USD. Both destinations include JCI-accredited hospital care; India additionally carries NABH accreditation, while UAE centres hold DHA (Dubai Health Authority) or DOH (Department of Health Abu Dhabi) licensing. All cost estimates from GAF Healthcare are provided as personalised, transparent quotes prior to travel — no hidden facility fees.

The required in-country stay before you are fit for international air travel depends entirely on the type and severity of your anaemia treatment. For uncomplicated iron-deficiency anaemia treated with intravenous iron infusion (1–3 sessions): most patients are fit to fly 5–7 days after their final infusion, once the treating haematologist confirms absence of adverse reaction and initial reticulocyte response is evident. Plan for a total in-country stay of approximately 7–10 days including diagnostic workup and infusion sessions. For vitamin B12 deficiency with neurological involvement requiring intramuscular hydroxocobalamin loading: a minimum 7–10 day stay is recommended to complete the loading regimen and assess early neurological stability; fit-to-fly is typically confirmed at Day 7–10. For complex haematological investigation including bone marrow biopsy: the biopsy itself is a day-procedure; however, awaiting final pathology, cytogenetics, and specialist review requires 10–14 days in-country. For aplastic anaemia patients commencing ATG-based immunosuppressive therapy: a minimum 3–4 week in-country stay is required, as ATG is administered over 4–5 consecutive days in hospital, followed by monitoring for serum sickness, granulocyte count recovery assessment, and initiation of oral maintenance medications (cyclosporine, eltrombopag). Your treating haematologist will issue a formal fit-to-fly certificate, and GAF Healthcare will schedule your departure transfer accordingly to prevent any premature departure risk.

Success rates for anaemia treatment are highly subtype-specific, and understanding realistic outcome benchmarks is critical for informed decision-making. For iron-deficiency anaemia treated with intravenous iron infusion: haemoglobin normalisation (Hb ≥12 g/dL in women, ≥13 g/dL in men) is achieved in 92–97% of patients within 8–12 weeks of a correctly dosed infusion protocol. Serum ferritin replenishment to >50 ng/mL is achieved in >95% of patients. For vitamin B12-deficiency megaloblastic anaemia: haematological response (reticulocyte rise by Day 5–10, Hb normalisation by 6–8 weeks) is seen in virtually 100% of patients with adequate cobalamin repletion; neurological recovery from subacute combined degeneration is partial and slower, with best outcomes when treatment begins within 3–6 months of neurological symptom onset. For autoimmune haemolytic anaemia treated with corticosteroids ± Rituximab: initial remission is achieved in 70–85% of patients; long-term remission in approximately 50–60% after steroid tapering. For severe aplastic anaemia treated with ATG + cyclosporine + eltrombopag: overall haematological response rates of 68–80% are reported in international trials (NEJM 2017 data), with complete response in approximately 58% at 6 months. For young patients (<40 years) undergoing matched sibling donor HSCT for severe aplastic anaemia: 5-year overall survival exceeds 90% at high-volume centres. JCI-accredited centres in India (Tata Memorial, Apollo, Medanta) and the UAE (Cleveland Clinic Abu Dhabi, American Hospital Dubai) report outcomes consistent with international benchmarks published by CIBMTR and EBMT. GAF Healthcare provides patients with centre-specific outcome data and haematologist profiles prior to commitment.